Literature DB >> 17329241

Prostaglandin E receptors.

Yukihiko Sugimoto1, Shuh Narumiya.   

Abstract

Prostaglandin (PG) E(2) exerts its actions by acting on a group of G-protein-coupled receptors (GPCRs). There are four GPCRs responding to PGE(2) designated subtypes EP1, EP2, EP3, and EP4 and multiple splicing isoforms of the subtype EP3. The EP subtypes exhibit differences in signal transduction, tissue localization, and regulation of expression. This molecular and biochemical heterogeneity of PGE receptors leads to PGE(2) being the most versatile prostanoid. Studies on knock-out mice deficient in each EP subtype have defined PGE(2) actions mediated by each subtype and identified the role each EP subtype plays in various physiological and pathophysiological responses. Here we review recent advances in PGE receptor research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329241     DOI: 10.1074/jbc.R600038200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  427 in total

1.  PGE2 decreases reactivity of human platelets by activating EP2 and EP4.

Authors:  James P Smith; Elias V Haddad; Jason D Downey; Richard M Breyer; Olivier Boutaud
Journal:  Thromb Res       Date:  2010-05-08       Impact factor: 3.944

2.  Prostaglandin E2 induces interleukin-6 expression in human chondrocytes via cAMP/protein kinase A- and phosphatidylinositol 3-kinase-dependent NF-kappaB activation.

Authors:  Pu Wang; Fei Zhu; Konstantinos Konstantopoulos
Journal:  Am J Physiol Cell Physiol       Date:  2010-03-24       Impact factor: 4.249

3.  Transforming growth factor-β induces microRNA-29b to promote murine alveolar macrophage dysfunction after bone marrow transplantation.

Authors:  Racquel Domingo-Gonzalez; Carol A Wilke; Steven K Huang; Yasmina Laouar; Jeanette P Brown; Christine M Freeman; Jeffrey L Curtis; Gregory A Yanik; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-31       Impact factor: 5.464

4.  Prostaglandin E2 stimulates the production of vascular endothelial growth factor through the E-prostanoid-2 receptor in cultured human lung fibroblasts.

Authors:  Masanori Nakanishi; Tadashi Sato; Yingji Li; Amy J Nelson; Maha Farid; Joel Michalski; Nobuhiro Kanaji; Xingqi Wang; Hesham Basma; Amol Patil; Jadvinder Goraya; Xiangde Liu; Shinsaku Togo; Myron L Toews; Olaf Holz; Kai-Christian Muller; Helgo Magnussen; Stephen I Rennard
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02       Impact factor: 6.914

5.  Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production.

Authors:  Marion Man-Ying Chan; Andrea Rossi Moore
Journal:  J Immunol       Date:  2010-04-30       Impact factor: 5.422

6.  Impaired pulmonary immunity post-bone marrow transplant.

Authors:  Stephanie M Coomes; Leah L N Hubbard; Bethany B Moore
Journal:  Immunol Res       Date:  2011-05       Impact factor: 2.829

7.  Cooperativity of E-prostanoid receptor subtypes in regulating signaling and growth inhibition in human airway smooth muscle.

Authors:  James V Michael; Adelina Gavrila; Ajay P Nayak; Tonio Pera; Jennifer R Liberato; Steven R Polischak; Sushrut D Shah; Deepak A Deshpande; Raymond B Penn
Journal:  FASEB J       Date:  2019-01-02       Impact factor: 5.191

8.  Identifying Mechanisms of Homeostatic Signaling in Fibroblast Differentiation.

Authors:  Hayley C Warsinske; Shanna L Ashley; Jennifer J Linderman; Bethany B Moore; Denise E Kirschner
Journal:  Bull Math Biol       Date:  2015-09-18       Impact factor: 1.758

9.  Prostaglandin E2 induces contraction of liver myofibroblasts by activating EP3 and FP prostanoid receptors.

Authors:  S Ayabe; T Murata; T Maruyama; M Hori; H Ozaki
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

10.  Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene.

Authors:  Jin Xu; Mingming Xu; Yasmin L Hurd; Gavril W Pasternak; Ying-Xian Pan
Journal:  J Neurochem       Date:  2008-12-10       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.